Rebecca A Lindsey Boyd, LPN | |
521 Stewart Dr, Abington, MA 02351-5027 | |
(617) 620-4080 | |
Not Available |
Full Name | Rebecca A Lindsey Boyd |
---|---|
Gender | Female |
Speciality | Licensed Practical Nurse |
Location | 521 Stewart Dr, Abington, Massachusetts |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1700279775 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
164W00000X | Licensed Practical Nurse | LN89861 (Massachusetts) | Primary |
Mailing Address | Practice Location Address |
---|---|
Rebecca A Lindsey Boyd, LPN 521 Stewart Dr, Abington, MA 02351-5027 Ph: (617) 620-4080 | Rebecca A Lindsey Boyd, LPN 521 Stewart Dr, Abington, MA 02351-5027 Ph: (617) 620-4080 |
News Archive
Researchers at the Monash Institute of Pharmaceutical Sciences and the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology have created a nanoparticle that could improve the properties of painkillers by delivering them directly to the source of pain.
Scientists from the National Institutes of Health in the United States have made an important discovery that should forever change the scope and direction of Alzheimer's research. Specifically, they have discovered that the protein tangles which are a hallmark of the disease involve at least three different proteins rather than just one.
Emerson Ecologics, LLC announces an expanded partnership with Gaia Herbs Professional Solutions as one of their two select distributors. Effective May 1st, Gaia Herbs is asking all of its Professional Solutions customers to order products through a distributor. Gaia Herbs Professional Solutions will be sold through distribution in order to advance the company's commitment to sustainability practices and provide enhanced ordering benefits to their healthcare practitioner customers.
Gleevec, a drug regarded by many as having "wonder drug" capabilities in the treatment of chronic myelogenous leukaemia (CML) and other cancers, has been revealed as having shortcomings in that some patients have undergone a relapse after building a resistance to the drug. For others with the advanced stage of the disease, the drug has failed to produce durable remissions.
› Verified 6 days ago